Novo Nordisk A/S, Eli Lilly and Company and Sanofi Accounts for More Than Half of the Market Share in Terms of Revenue

Accessibility of low-priced Insulin supported by growing investments in R&D is likely to boost the growth of insulin segment in the global diabetes drugs market

Format

PNG

Source

Fortune Business Insights

Novo Nordisk A/S, Eli Lilly and Company and Sanofi Accounts for More Than Half of the Market Share in Terms of Revenue

Format

Source

Downloads